OncoMatch/Clinical Trials/NCT07320586
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Is NCT07320586 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Nab paclitaxel for gastric cancer.
Treatment: Camrelizumab · Nab paclitaxel — This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included in each population, and a total of 40 subjects were planned to be included.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) negative
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: systemic chemotherapy — first-line
Gastric cancer patients who have previously received first-line systemic chemotherapy (queue 1) or systemic chemotherapy combined with immunotherapy (queue 2) for progression
Cannot have received: paclitaxel (paclitaxel)
Patients who have received previous treatment with paclitaxel drugs
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 10^9/L, platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L
Kidney function
CrCl ≥ 60 ml/min/1.73 m2 (Cockcroft Gault formula)
Liver function
serum total bilirubin ≤ 1.5x ULN, AST and ALT ≤ 2.5x ULN (≤ 5x ULN if liver metastasis)
The main organ functions well and the laboratory test data meets the following standards: (1) Blood routine: absolute neutrophil count ≥ 1.5 × 10^9/L (or greater than the lower limit of normal laboratory values in the research center), platelet count ≥ 100 × 10^9/L, hemoglobin ≥ 90g/L; (2) Liver function: serum total bilirubin ≤ 1.5 times the upper limit of the standard value (ULN), AST and ALT ≤ 2.5 times ULN. If the patient has liver metastasis, this standard is ≤ 5 times ULN; (3) Renal function: CrCl ≥ 60 ml/min/1.73 m2 (calculated according to the Cockcroft Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07320586 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior paclitaxel disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages